A5011353416- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Intraperitoneal and Appendiceal Malignancies
- Cancer Treatment and Pharmacology
- Endometriosis Research and Treatment
- PARP inhibition in cancer therapy
- Chemotherapy-related skin toxicity
- Cancer, Lipids, and Metabolism
- Cancer survivorship and care
- BRCA gene mutations in cancer
- Cancer Mechanisms and Therapy
- Cancer Research and Treatments
- Renal cell carcinoma treatment
- Uterine Myomas and Treatments
- Nail Diseases and Treatments
- Nutrition and Health in Aging
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Reproductive Biology and Fertility
- Cancer-related molecular mechanisms research
- Bladder and Urothelial Cancer Treatments
- Lymphoma Diagnosis and Treatment
Charité - Universitätsmedizin Berlin
2016-2025
Humboldt-Universität zu Berlin
2017-2024
Freie Universität Berlin
2017-2024
Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie
2017-2023
Australia New Zealand Gynaecological Oncology Group
2019
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2018
Innsbruck Medical University
2015
Kliniken Essen-Mitte
2013
Laser- und Medizin-Technologie (Germany)
2009
University of Cologne
2006
Resource3 February 2020Open Access Source DataTransparent process Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment Karen Hoffmann Department Molecular Biology, Max Planck Institute for Infection Berlin, Germany Search more papers by this author Hilmar Berger Hagen Kulbe Gynecology, Charité University Medicine, Campus Virchow-Klinikum, Sukanija Thillainadarasan Hans-Joachim Mollenkopf Tomasz Zemojtel BIH Genomics Core Unit, Eliane Taube Pathology,...
<h3>Objective</h3> The objective of the study was to evaluate prognostic impact residual tumor size after cytoreductive surgery in patients with epithelial ovarian cancer. <h3>Methods</h3> In this prospective, multicenter study, 226 cancer (International Federation Gynecology and Obstetrics stages IIA–IV) were included. Patients treated adjuvant platinum-based chemotherapy. Univariate multivariable survival analyses performed investigate on progression-free overall survival. <h3>Results</h3>...
MicroRNA (miRNA) deregulation is a hallmark of human cancer. However, the mechanisms underlying miRNA alteration and specific role proteins involved in processing remains to be elucidated. Dicer key enzyme pathway that essential for production mature miRNAs from their precursors. We tested hypothesis has biological clinical relevance ovarian cancer, using range methods including vitro manipulation expression. observed down-regulation subgroup carcinomas, found decreased expression correlates...
Abstract Background This trial investigated the hypothesis that treatment with trabectedin/PLD (TP) to extend platinum-free interval (TFIp) can improve overall survival (OS) in patients recurrent ovarian cancer (OC). Methods Patients OC (up two previous platinum-based lines), a TFIp of 6–12 months, were randomised receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). Results study enrolled 617 patients. median 8.3 months and 30.3%...
PURPOSE Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) the phase III Study 309/KEYNOTE-775. We report results from III, randomized, open-label European Network of Gynaecological Oncological Trial-en9/LEAP-001 study (ClinicalTrials.gov identifier: NCT03884101 ) that evaluated len pembro first-line aEC. METHODS Patients with stage to IV...
Approximately one third of women diagnosed with ovarian cancer is 70 years or older. Information on the treatment reality these elderly patients limited.275 primary epithelial FIGO stage II-IV undergoing cytoreductive surgery and platinum-based chemotherapy were prospectively included in this European multicenter study. Patients <70 ≥70 compared regarding clinicopathological variables prognosis.Median age was 58 (18-85); 47 (17.1%) The postoperative 60-day-mortality rate 2.1% for 0.4%...
The Sixth Framework Program European Union project OVCAD, "Ovarian Cancer-Diagnosis of a Silent Killer," aimed to investigate new predictors for early detection minimal residual disease in epithelial ovarian cancer (EOC). Here we present the main pathologic, surgical, and chemotherapy characteristics OVCAD patient cohort.Between February 2005 December 2008, 5 gynecologic centers (WP2 group) enrolled prospective 275 consecutive patients with EOC into this translational study. Inclusion...
Detection of epithelial ovarian cancer (EOC) poses a critical medical challenge. However, novel biomarkers for diagnosis remain to be discovered. Therefore, innovative approaches are the utmost importance patient outcome. Here, we present concept blood-based biomarker discovery, investigating both and specifically stromal compartments, which have been neglected in search candidates. We queried gene expression profiles EOC including microdissected epithelium adjacent stroma from benign...
The phase III LION trial found no therapeutic benefit from systematic lymphadenectomy in patients with advanced ovarian cancer optimal upfront cytoreduction and normal-appearing lymph nodes. Patients were randomized intra-operatively, excluding those who could not be operated on when they tumor-free or had suspicious/bulky nodes upon inspection palpation. This analysis focused the outcomes of group excluded because bulky alone. was a monocentric, retrospective subgroup controlled conducted...
Abstract Background The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection cells from apoptosis and oxidative stress has just started investigated ovarian cancer. TRAP1 been shown estrogen up-regulated α (ERα) positive cancer cells. clinical impact is not clear so far significance ERα expression as therapeutic prognostic marker still controversial. Therefore, we importance together with regard clinicopathological parameters,...
Background: Malnutrition was associated with worse survival outcomes, impaired quality of life, and deteriorated performance status across various cancer types. We aimed to identify risk factors for malnutrition in patients epithelial ovarian (EOC) impact on survival. Methods: In our prospective observational monocentric study, we included the primary recurrent EOC, tubal or peritoneal conducted. assessed serum laboratory parameters, body mass index, nutritional screening score (NRS-2002),...
The concept of the online tumor conference was established in 2004 as a pilot project. We developed specific web-based software to organize and conduct board meetings gynecologists, surgeons, radiologists, oncologists, pathologists from different hospitals gynecological practitioners, discussing individual patient's cases, defining therapy options, exchanging clinical experience. Following didactic approach, patient data are presented participants, with special focus toward preference late...
Purpose Enzastaurin is an oral serine/threonine kinase inhibitor antitumor agent. Our phase II trial tested the efficacy and safety of enzastaurin added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed advanced ovarian cancer. Patients Methods This was randomized, placebo-controlled study International Federation Gynecology Obstetrics stage IIB IV ovarian, fallopian tube, or peritoneal epithelial carcinoma. were randomly assigned six cycles...